Selective 7-Substituted Purine Antibacterials for C. diff
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibacterial agents are ineffective against Clostridium difficile (C. diff.) infections, which often arise as a result of antibiotic treatment, and there is a need for compounds that selectively target C. diff. without affecting other beneficial anaerobic bacteria.
Innovation Solution
Development of 7-substituted 2-benzylamino-6-oxopurine compounds and their salts, which exhibit potent activity against C. diff. while having weak activity against other intestinal Gram-positive anaerobes, thereby reducing the likelihood of developing or treating C. diff.-associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibacterial agents are used to treat C. diff. infections, then broad-spectrum bacterial coverage is achieved, but beneficial intestinal anaerobes are also affected and drug resistance develops
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (7-substituted-2-benzylamino-6-oxopurines) that have differentiated interaction properties with C. diff. versus other anaerobes. The selective toxicity arises from the compound's ability to target C. diff.-specific cellular mechanisms while sparing beneficial bacteria, achieving localized therapeutic effect without broad-spectrum damage
Solution Approach 2:
The patent employs parameter changes by systematically varying the R1 substituent groups on the purine core structure to optimize selectivity. Different substituents (halogenated alkyl groups, cycloalkyl groups, heterocyclic groups) were evaluated to tune the compound's affinity for C. diff. targets versus other anaerobes, achieving the desired selective profile through structural parameter optimization
2Reliability
If current antibiotics are administered to prevent C. diff. infection, then C. diff. growth is inhibited, but other intestinal flora are disrupted and resistance is selected
Solution Approach 1:
The compounds exhibit local quality in their antimicrobial spectrum, being specifically active against C. diff. while maintaining selectivity that spares beneficial intestinal anaerobes. This targeted approach allows prophylactic use without the broad-spectrum flora disruption characteristic of conventional antibiotics
Solution Approach 2:
The patent converts the historical harm of antibiotic use (which causes C. diff. infections by disrupting flora) into a benefit by developing compounds that specifically target C. diff. without harming beneficial anaerobes. The selective mechanism transforms the problem of flora disruption into a solution that preserves intestinal microbiome integrity while providing prophylactic protection
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The invention features compounds of formula (I): The compounds are useful as antibacterial agents, especially again Clostridium difficile-associated diseases.